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The Rac1/Cdc42 effector p21-activated kinase (PAK)
is activated by various signaling cascades including
receptor-tyrosine kinases and integrins and regulates
a number of processes such as cell proliferation and
motility. PAK activity has been shown to be required
for maximal activation of the canonical Ras/Raf/MEK/
ERK Map kinase signaling cascade, likely because of
PAK co-activation of Raf and MEK. Herein, we found
that adhesion signaling also stimulates an association
between PAK1 and ERK1/2. PAK1 and ERK1/2 co-im-
munoprecipitated from rat aortic smooth muscle cells
(SMC) plated on fibronectin, and the two proteins co-
localized in membrane ruffles and adhesion complexes
following PDGF-BB or sphingosine 1-phosphate treat-
ment, respectively. Far Western analysis demon-
strated a direct association between the two proteins,
and peptide mapping identified an ERK2 binding site
within the autoinhibitory domain of PAK1. Interest-
ingly, deletion of a major ERK binding site in PAK
attenuates activation of an ERK-dependent serum-re-
sponsive element (SRE)-luciferase reporter gene, indi-
cating that association between PAK and ERK is re-
quired to facilitate ERK signaling. We also show that
ERK2 phosphorylates PAK1 on Thr212 in vitro and that
Thr212 is phosphorylated in smooth muscle cells fol-
lowing PDGF-BB treatment in an adhesion- and MEK/
ERK-dependent fashion. Expression of a phospho-
mimic variant, PAK-T212E, does not alter ERK
association, but markedly attenuates downstream
ERK signaling. Taken together, these data suggest that
PAK1 may facilitate ERK signaling by serving as a
scaffold to recruit Raf, MEK, and ERK to adhesion
complexes, and that subsequent growth factor-stimu-
lated phosphorylation of PAK-Thr212 by ERK may
serve to provide a negative feedback signal to control
coordinate activation of ERK by growth factor- and
matrix-induced signals.
The Ras superfamily of small GTPases including H-Ras,
R-Ras, and Rho family members (Rac, Rho, and Cdc42) among
others are activated by numerous transmembrane receptors
such as receptor-tyrosine kinases, G-protein-coupled receptors,
and integrins and regulate a variety of cellular processes in-
cluding proliferation, differentiation, and migration (1). These
GTPases are molecular switches that cycle between an active
GTP-bound state and an inactive GDP-bound state (2, 3). In
the GTP-bound form, the Ras-related GTPases interact with
and activate a number of effector molecules that have been
implicated in regulating cell cycle progression and/or cell
migration such as the serine/threonine protein kinases, lipid
kinases, and actin-binding/scaffolding proteins (3, 4).
Ras and Rac regulate MAP1 kinase signaling, and a variety
of agonists use Ras-dependent activation of ERK and/or Rac-
dependent activation of c-Jun N-terminal kinase as dominant
mitogenic signaling pathways (5). MAPK activation typically
occurs by highly conserved multilevel kinase cascades (i.e.
Ste20/Ste11/Ste7/Fus3 in yeast and Raf/MEK/ERK in mamma-
lian cells) eventually leading to MAPK nuclear translocation
and transcription factor activation (6, 7). Although the mam-
malian MAPK signaling pathways were initially thought to be
independent and parallel, recent studies indicate that there is
significant cross-talk between them.
Several lines of evidence indicate that integrins and growth
factors promote coordinated activation of the ERK signaling
cascade. Integrin signaling has been shown to be required for
maximal activation of either growth factor-stimulated Raf or
MEK activation an event likely dependent on the specific inte-
grin receptors engaged in the particular cell type used (8–10).
Studies indicate that the Rac effector, p21-activated protein
kinase (PAK), a homologue to the yeast MAP4K, Ste20, may
serve as a convergence point between growth factor- and inte-
grin-mediated Ras/ERK signaling. GTP-bound Rac and Cdc42
activate PAK1 in an adhesion-dependent fashion by binding to
the p21-binding domain (PBD or CRIB) localized within the
N-terminal autoinhibitory domain of PAKs 1–3 (11, 12). This
interaction exposes the PAK C-terminal kinase domain permit-
ting activation, autophosphorylation, and downstream signal-
ing (13, 14). Notably, plating cells on the extracellular matrix
fibronectin enhances the ability of Rac to activate PAK, and 1
integrins have been shown to transmit signals downstream to
c-Jun N-terminal kinase through the PI 3-kinase/Rac/PAK
cascade (15, 16).
Interestingly, Howe et al. (17) demonstrated that inhibition
of PAK attenuated integrin-dependent ERK activation, and
subsequent studies showed that this was likely because of the
ability of PAK to enhance adhesion-dependent Raf and/or MEK
activation. Activated PAK associates with Raf and phosphoryl-
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ates Ser338 and Ser339 within the catalytic domain. Although
several phosphorylation sites have been reported to be neces-
sary for Raf activation, phosphorylation of these serines has
been shown to be essential for maximal Raf activation by Ras in
response to integrin-mediated PAK1 activation (14, 18). How-
ever, the convergence of integrin signaling at the level of Raf is
controversial, and at least one study refutes the necessity of
PAK3 for Ser338 phosphorylation in response to epidermal
growth factor (19). Recent studies indicate that PAK also phos-
phorylates MEK on a site (Ser298) that is necessary for maxi-
mal MEK activation by Raf and that adhesion-dependent PAK
signaling enhances association between MEK and ERK (5,
20–22). Thus, convergence of these two well established path-
ways likely occurs at the level of PAK, which can effect ERK
signaling at multiple levels including co-activation of Raf and
MEK. Whether the pathways leading from PAK to ERK are
differentially regulated in an integrin-dependent cell type-spe-
cific fashion are important questions that remain to be
addressed.
Herein, we report that adhesion signaling induces a direct
association between ERK and PAK1. Taken together with pre-
vious data, our results indicate that PAK may coordinate sig-
naling between Raf, MEK, and ERK by acting as a scaffold for
these proteins. We also present evidence that ERK2 phospho-
rylates PAK1 on Thr212, a site just downstream of the ERK
binding site on PAK, and that this event may provide negative
feedback inhibition of ERK signaling. These data highlight yet
another level whereby adhesion signaling may regulate syn-
ergy between Ras and Rho family proteins to dynamically
regulate the activation state of ERK at distinct regions within
the cell.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—The phosphospecific ERK1/2 antibody and
the anti-PAK1 antibody were purchased from Cell Signaling. The phos-
pho-Tyr15 Cdc2 antibody was purchased from Santa Cruz Biotechnol-
ogy. The phosphospecific PAK-Thr212 antibody, anti-FLAG (M5), anti-
acetylated tubulin and anti-vinculin antibodies, alsterpaullone and
fibronectin were purchased from Sigma. PDGF-BB and UO126 were
purchased from Calbiochem. The purified active ERK2 and anti-ERK2
antibody were purchased from UBI. The anti-paxillin antibody was
purchased from Transduction Laboratories, and Texas-Red phalloidin
was purchased from Molecular Probes.
Expression Constructs—Rat His-PAK1 and His-ERK2 (wild-type and
kinase-defective) constructs were generous gifts from Leslie Parise
(UNC) and Melanie Cobb (UTSW), respectively. GFP-PAK1 was made
by inserting full-length wild-type human PAK1 (generous gift from
Alan Howe, UVT) into EGFP-C1 vector (Clontech) cut with BglI
EcoR1. GST-PAK1 (amino acids 1–290) was constructed as described
previously (23). S212E/A and S223A variants were generated by PCR
site-directed mutagenesis of GST- or GFP-tagged PAK1 constructs.
Forward and reverse complementary primers corresponding to the fol-
lowing sequence were used: for PAK1-S212A, 5: GAACCACTTCCT-
GTCGCTCCAACTCGGGACGTGG, for S212E, 5: GTGATTGAAC-
CACTTCCTGTCGAACCAACTCGGGACGTGGC, for PAK1-S223A, 5:
GGCTACATCTCCCATTGCACCTACTGAAAATAACACC. Mutations
were confirmed by direct sequencing.
Cell Culture and Agonist Treatment—Rat aortic smooth muscle cells
(SMC) were obtained from rat thoracic aortas by enzymatic digestion as
described previously (24). Cells were used from passages 7–21 and were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)-F12 plus
10% fetal bovine serum and 1% penicillin-streptomycin. In some experi-
ments, cells were serum-starved for 4 h before treatment with PDGF-BB
(20 ng/ml) for the times indicated. For adhesion suspension experiments,
cells were trypsinized, neutralized in soybean trypsin inhibitor (1 mg/ml
in PBS), collected by centrifugation, and resuspended in serum-free
DMEM:F12 plus 1% penicillin-streptomycin. Cells were held in suspen-
sion or plated on fibronectin-coated (40 g/ml) dishes for the indicated
times. A7R5 (ATCC) smooth muscle cells were maintained in DMEM plus
10% fetal bovine serum and 1% penicillin-streptomycin.
Protein Purification—His-ERK2 (wild-type and kinase-defective)
and His-PAK1 were purified from bacterial lysates using Qiagen nickel-
NTA (nickel-nitriloacetic acid) -agarose according to the manufacturer’s
protocol (The QIAexpressionisttm 5th Ed.). Briefly, cleared lysates in a
buffer containing 50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH
8.0 plus 1 mg/ml lysozyme, 1 mM Na3VO4, 40 mM NaF, 100 M leupep-
tin, 1 mM AEBSF (4-(2-aminoethyl)-benzenesulfonyl fluoride), and 0.05
TIU/ml aprotinin were combined with 1 ml of nickel-NTA-agarose,
rotated for 1 h at 4 °C, and then transferred to a chromatography
column. The His-ERK nickel-NTA-agarose complexes were washed
three times with 50 mM imidazole wash buffer (50 mM NaH2PO4, 300
mM NaCl, 50 mM imidazole, pH 8.0) and eluted with 250 mM imidazole
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH
8.0). The His-PAK1 nickel-NTA-agarose complex was washed three
times with 30 mM imidazole wash buffer (50 mM NaH2PO4, 300 mM
NaCl, 30 mM imidazole, pH 8.0) and one time with 40 mM imidazole
wash buffer (50 mM NaH2PO4, 300 mM NaCl, 40 mM imidazole, pH 8.0).
25 l of each elution fraction was analyzed by SDS-PAGE to determine
the appropriate fractions to pool. Proteins were dialyzed (50 mM Hepes,
150 mM NaCl, and 10% glycerol) overnight at 4 °C and then aliquoted
and stored at 80 °C for subsequent experiments.
GST Pull-down Assay—GST-PAK (amino acids 1–290 of PAK1,
J. Chernoff) was purified from bacterial lysates using glutathione-
agarose beads (Amersham Biosciences) as described previously (23).
SMC were incubated in serum-free medium (DMEM:F12 plus 1% pen-
icillin-streptomycin) and treated with PDGF-BB (20 ng/ml) as described
above. Cells were lysed in Buffer A (50 mM Tris, pH 7.6, 500 mM NaCl,
0.1% SDS, 0.5% deoxycholate, 1% Triton X-100, 0.5 mM MgCl2, plus
protease inhibitors), and 500 g of protein were combined with 30 g of
GST-PAK1 fusion protein and rotated for 30–60 min at 4 °C. The beads
were then washed twice with Buffer B (50 mM Tris, pH 7.6, 150 mM
NaCl, 1% Triton X-100, 0.5 mM MgCl2, plus protease inhibitors) and
once with Tris-buffered saline (TBS, 0.2 M NaCl, 50 mM Tris-HCl, pH
7.4). The beads were resuspended in SDS-PAGE sample buffer, boiled
for 5 min, electrophoresed on a 12% SDS-polyacrylamide gel, and ana-
lyzed by Western blotting using either an anti-pERK1/2 or anti-ERK2
antibodies (1:1,000).
In Vitro Kinase Assay—To detect ERK phosphorylation, purified
His-ERK2 (kinase-dead, 0.1–1 g), and His-PAK1 (0.1–0.5 g) were
incubated with 10 Ci of [-32P]ATP in kinase buffer (50 mM Hepes pH
7.3, 10 mM MgCl2, 1 mM MnCl2, 5 mM NaF, 0.25% Triton 100-X) for 10
min at 30 °C. To detect phosphorylation of PAK1, freshly purified GST,
GST-PAK1-(1–290), or GST-PAK1 variants (5 g) were incubated with
10 ng of active ERK2 (UBI) in kinase buffer in the presence of 50 M
ATP with or without [-P32]ATP (10 Ci)) for 10 min at 30 °C. Samples
were resolved by SDS-PAGE. The radioactive gels were fixed in 50%
methanol, 10% acetic acid, and 20% glycerol for 20 min and then
rehydrated for 90 min in 7% acetic acid 5% methanol, and 20% glycerol.
The gel was dried for 2 h at 80 °C and then was exposed to Kodak XAR
autoradiograph film. The gel was then rehydrated in ddH2O and then
stained with 1% Coomassie Blue. For non-radioactive kinase assays,
the gel was transferred to nitrocellulose, and analyzed by Western
blotting using the phospho-Thr212 antibody.
Western Blotting—Western blots were performed using the appro-
priate antibodies at a 1:1000 dilution. Blots were washed in TBST
(TBS plus 0.05% Triton-X), followed by incubation with either horse-
radish peroxidase-conjugated rabbit anti-mouse antibody or -protein
A-Sepharose (Amersham Biosciences) at a 1:2000 dilution. Blots were
visualized after incubation with chemiluminescence reagents (ECL,
Amersham Biosciences).
Far Western—Purified GST and GST-PAK1 beads were electropho-
resed by SDS-PAGE (12%) and transferred to nitrocellulose. The blot
was incubated in 5% powdered milk/TBST  0.2% sodium azide for 48 h
at 4 °C (to block the membrane and renature proteins). The blot was
then incubated with purified His-ERK2 (8 g/ml in 5% powdered milk/
TBST) overnight at 4 °C. The blot was washed three times (10 min) with
TBST and then incubated with India HisProbe-HRP (1:5,000 Pierce) for
1 h at room temperature. The blot was washed with TBST overnight
at 4 °C before detection with SuperSignal West Pico (Pierce) chemi-
luminescence substrate.
PAK1 Spot Blot—A membrane containing 12-mer overlapping pep-
tides derived from the PAK1 sequence was prepared by SPOT synthesis
(ABIMED, generously provided by Leslie Parise). The PAK1 spot blot
was blocked with 10% powdered milk in TBS-T, followed by incubation
with 2 g/ml purified His-ERK2 in binding buffer (20 mM Hepes pH 7.4,
150 mM NaCl, 1% glycerol, 5% bovine serum albumin, and 0.05% Tween
20), overnight at 4 °C. The blot was washed three times (10 min) with
TBST. The blot was then incubated with anti-ERK2 antibody, followed
by incubation with horseradish peroxidase-conjugated protein A-Sepha-
rose at a 1:2000 dilution, and visualized by chemiluminescence (ECL).
Luciferase Assay—A7R5 cells were transfected with 0.75 g of SRE-
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luciferase reporter construct and 0.25 g of the GFP construct variant
per well using Superfect (Stratagene) following the manufacturer’s
protocol. All transfections were done in quadruplicate. Luciferase as-
says were performed 48-h post-transfection using Steady-Glo Lucifer-
ase Assay kit (Promega) following the manufacturer’s protocol. Relative
promoter activity was expressed as the mean  S.E. relative to total
protein.
Immunocytochemistry—A7R5 cells were transfected with the desired
GFP-tagged construct using Superfect (Qiagen). After 48 h, the cells
were trypsinized, rinsed in soybean trypsin inhibitor (1 mg/ml), centri-
fuged, washed twice in PBS, and resuspended in serum-free DMEM
plus 1% penicillin-streptomycin. Cells were counted and plated on fi-
bronectin-coated (10 g/ml) slides (Lab-Tek) for 20–90 min. Staining
procedure was followed as previously published (25). In brief, cells were
fixed with 4% paraformaldehyde, permeabilized with 4% Triton X-100
in PBS, incubated with specified primary antibody for 1 h at the fol-
lowing concentrations: anti-perk 1:200, anti-vinculin 1:50, anti-paxillin
1:250, anti-acetylated tubulin (1:1000). After washing with PBS, slides
were incubated for 1 h with either Texas Red-conjugated donkey anti-
rabbit or donkey anti-mouse antibodies (2 g/ml) or Texas Red-conju-
gated phalloidin to detect filamentous actin.
Mass Spectral Analysis—GST-PAK1 (amino acids 1–290, 10 g) was
electrophoresed on a 14% precast Tris-glycine SDS-PAGE gel (Invitro-
gen). The gel was fixed by soaking in 25% isopropyl alcohol/10% acetic
acid for 20 min, stained with 0.01% Coomassie Blue in 10% acetic acid
overnight, followed by destaining in 10% acetic acid. Appropriate bands
were excised, trypsinized, and peptides were eluted and subjected to
MALDI-TOF/TOF (ABI 4700 Proteomics Analyzer) and LC-MS (Micro-
mass Q/TOF API-US LC/MS/MS) to define the cleavage site as de-
scribed previously (26).
RESULTS
We reported previously that inhibition of FAK in SMC by
ectopic overexpression of its dominant-interfering form FAK-
related non-kinase (FRNK) did not attenuate the magnitude or
duration of total cellular ERK activity induced by PDGF-BB,
angiotensin II, or fibronectin. However, recent studies indicate
that active ERK is localized in several different compartments
within the cell including focal adhesions (21, 27–29). To deter-
mine whether adhesion-dependent FAK signaling might regu-
late activation of ERK at distinct sites within the cell, we
plated GFP-FRNK-transfected SMC on fibronectin for 60 min
and stained cells with an antibody that recognizes active (phos-
phorylated) ERK1/2. As shown in Fig. 1, ectopic expression of
FRNK does dramatically reduce adhesion-stimulated ERK ac-
tivation in focal adhesions.
In light of our previous data revealing that FRNK expression
markedly attenuated integrin-stimulated Rac1 activity, and
mounting evidence that the Rac1 effector, PAK regulates ERK
activity in vivo in an adhesion-dependent fashion, we examined
whether PAK might be involved in regulating ERK activation
in focal adhesions. As shown in Fig. 2A, ectopically expressed
GFP-PAK and phospho-ERK1/2 co-localize in membrane ruf-
fles following PDGF-BB stimulation and co-localize within nas-
cent focal adhesions following sphingosine 1-phosphate treat-
ment when SMC are plated on fibronectin. In addition,
immunoprecipitation experiments revealed an adhesion-
dependent association of endogenous ERK1/2 and PAK1 in
SMC. SMC were either continuously grown in serum (denoted
A, for attached) or trypsinized and held in suspension (S) in
serum-free medium and/or plated on fibronectin (FN)-coated
plates for the times indicated. As shown in Fig. 2B, association
between PAK and ERK appears to peak after 60 min and
surpasses the amount co-immunoprecipitated in stably adher-
ent cells. Very little of the PAK1-ERK complex was formed in
non-adherent cells, as might be expected, because activation of
PAK is dependent on adhesion signaling (30). Taken together,
these data support the hypothesis that PAK1 and ERK1/2
associate in intact cells.
Interestingly, we showed that a GST-PAK1 fusion protein
containing the N-terminal 290 amino acids of PAK1 could
efficiently precipitate phosphorylated ERK1/2 from SMC ly-
sates, indicating that the N terminus of PAK is sufficient for
ERK binding (Fig. 3A). Subsequent experiments, in which
ERK2 was precipitated from serum-starved SMC or SMC
treated with 20 ng/ml PDGF-BB for 10 min (to maximally
activate ERK), revealed that phosphorylated (active) and un-
phosphorylated (inactive) ERK2 are precipitated equally well
with the PAK1 fusion protein (Fig. 3B), indicating that preac-
tivation of ERK was not required for PAK1 binding.
Previous studies have shown that Raf also binds to PAK;
however, the binding site for Raf is located within the C ter-
minus of PAK (in a region not included in our GST-PAK1
construct). Thus it was unlikely that ERK was precipitated by
an indirect association with Raf and its binding partner MEK.
Nonetheless, a number of proteins have been shown to associ-
ate with the N terminus of PAK, including the small GTPases
Rac and Cdc42 and the adapter proteins NCK, GRB2, and PKL
(31–33). Therefore to further rule out the possibility of an
indirect ERK-PAK1 association, we used a Far Western ap-
proach. We probed a membrane containing increasing amounts
of GST-PAK1 fusion protein with purified His-ERK2 protein
and processed the membrane by Western blotting with an
FIG. 1. GFP-FRNK expression attenuates ERK activity in focal
adhesions. SMC were transfected with GFP-FRNK and plated on
fibronectin-coated chamber slides (10 g/ml) for 90 min in the presence
of serum. Cells were fixed as described under “Experimental Proce-
dures” and stained with an antiphospho-ERK antibody (1:200) followed
by a Texas Red-conjugated donkey anti-rabbit antibody (2 g/ml). GFP-
FRNK was visualized by direct fluorescence.
FIG. 2. ERK1/2 and GFP-PAK1 co-localize, and endogenous
ERK1/2 and PAK1 associate in SMC plated on fibronectin. A,
A7R5 cells were transfected with GFP-PAK1 and plated on fibronectin-
coated slides in serum-free media. After 45 min, cells were treated with
PDGF-BB (20 ng/ml) or sphingosine 1-phosphate (S1p; 1 M) for and
additional 45 min. Endogenous pERK and ectopically expressed GFP-
PAK1 co-localize in membrane ruffles and focal adhesions, respectively
as indicated by arrowheads. B, rat aortic SMC were either left attached
(A) or trypsinized and held in suspension for 90 min (S) or plated on 40
g/ml fibronectin (FN) for indicated times. Cells were lysed, and endog-
enous ERK was immunoprecipitated (IP) using an anti-pERK1/2 anti-
body as outlined under “Experimental Procedures.” Western blotting
(IB) was performed with anti-PAK1 and anti-ERK antibodies. Bottom
panels show a 5% lysate loading control for PAK1 and ERK1/2. Data in
Fig. 2 are representative of three separate experiments.
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anti-His antibody. As shown in Fig. 4A, purified His-ERK2
binds directly to GST-PAK1 in a concentration-dependent fash-
ion. In separate experiments, the binding of His-ERK2 to GST-
PAK1 was also detected using ERK-specific antibodies (data
not shown). It should be noted that in most preparations of
GST-PAK1–290, we observe the full-length product as well as
one major putative cleavage product (Fig. 4B). Interestingly,
His-ERK2 also readily associated with the presumptive cleav-
age product, but did not associate with GST alone (Fig. 4C). In
order to identify the nature of the breakdown product, we
isolated the full-length band (denoted P1) and the cleavage
product (denoted P2) from a Coomassie Blue-stained polyacryl-
amide gel and submitted the bands for mass spectral analysis.
A combination of MALDI-TOF/TOF and LC-MS data revealed
that P1 corresponded to GST fused to N-terminal amino acids
1–290 of PAK1 (as expected) while P2 corresponded to GST
fused to PAK1 amino acids 1–55. The PAK sequence from 1–55
appeared to be sufficient for ERK2 binding, but the observation
that ERK2 bound the larger 1–290 fragment slightly better
(compare amounts precipitated with 0.5 g of fusion protein in
Fig. 4, A versus C) indicates that additional sites within the
56–290 region may also be important.
In order to further map the interaction site on PAK1 for
ERK2, a membrane containing immobilized 12-mer peptides
derived from the amino acid sequence of PAK1 was incubated
with purified His-ERK2 and subsequently probed with an anti-
ERK2 antibody. As shown in Fig. 4D, interactions were de-
tected in three distinct regions corresponding to amino acids
40–54 (site A), 86–94 (site B), and 124–138 (site C) of PAK1.
All three binding sites are within the autoinhibitory domain of
PAK. Site B is within the CRIB domain that is responsible for
binding to Cdc42 and Rac while sites A and C flank this region.
Coupled with the result from the previous experiment, these
data indicate that amino residues 40–54 within PAK1 are
sufficient for ERK2 binding, but that additional interactions
within the CRIB domain and autoinhibitory domain may be
required for a high affinity interaction. Interestingly, crystal
structure analysis of the autoinhibitory domain of PAK1
(amino acids 70–149) revealed that sites B and C, which form
a -sheet and -helix, respectively, are in close proximity,
indicating that this region may provide a single docking site for
ERK (34).
Consistent with the idea that ERK makes multiple contacts
within the PAK1 N terminus, a GST-PAK fusion protein with a
deletion of amino acids 40–54 (GST-PAKdA) greatly reduces,
but does not completely block PAK-ERK association (Fig. 5A).
GST-PAKdA and GST-PAK-(1–290) did however precipitate
comparable amounts of Rac1 from SMC lysates, indicating that
the tertiary structure of the CRIB domain in this deletion
construct is likely intact (Fig. 5A, bottom panel). To determine
the effect of the PAK-ERK interaction on ERK signaling, we
generated a similar deletion (delta amino acids 40–54) in the
context of full-length GFP-PAK (GFP-PAKdA). This mutation
did not affect PAK localization to focal adhesions (data not
shown). We then co-transfected either GFP-PAK or GFP-
PAKdA along with a serum-responsive element (SRE)-
luciferase reporter construct and measured the activity of this
ERK-dependent transgene. In the presence of serum, GFP-
PAK expression significantly enhanced SRE-LUC activity,
whereas GFP-PAKdA expression did not (Fig. 5B). These
results indicate that PAK/ERK association is important for
PAK-dependent ERK signaling.
Because we mapped the binding site of ERK2 to the autoin-
hibitory domain of PAK1, we reasoned that ERK binding to
PAK might relieve autoinhibition and activate PAK by a mech-
anism similar to that observed for Rac or Cdc42. To address
this question, we incubated purified kinase-defective ERK2
(KD-ERK2) with purified His-PAK1 and performed an in vitro
kinase assay. As shown in Fig. 6, purified His-PAK1 autophos-
phorylates in a concentration-dependent fashion; however, ti-
tration of KD-ERK2 (up to a 15-fold molar excess over PAK)
into the reaction does not enhance PAK1 autophosphorylation.
Actually, KD-ERK2 appeared to attenuate PAK activity at the
higher concentrations (0.25–1 g), but the significance of this
inhibition is unclear. This experiment also revealed that PAK1
does not phosphorylate ERK2 in vitro as evident by the lack of
radioactivity incorporated into KD-ERK2.
In terms of the reciprocal phosphorylation event, PAK1 con-
tains two consensus sites for ERK phosphorylation, PVTP
(Thr212) and PISP (Ser223) just downstream of the defined
ERK2 binding site. To determine whether ERK2 phosphoryl-
ates PAK1 directly, we performed an in vitro kinase assay in
which a GST-PAK1 fusion protein containing the two putative
phosphorylation sites (amino acids 1–290) was incubated with
purified active ERK2 and [-32P]ATP. Fig. 7A shows that the
N-terminal GST-PAK1 fusion protein, but not GST alone, was
efficiently phosphorylated by ERK2 in vitro. Based on this
observation, we mutated each of the consensus amino acids to
alanine individually and in combination to determine if these
sites were phosphorylated by ERK2 in vitro. As shown in Fig.
7B, the T212A mutation dramatically reduced ERK-mediated
phosphorylation. The S223A mutation had only a slight effect
on its own or in combination with T212A. To confirm these
data, ERK2-mediated phosphorylation of Thr212 was measured
using a phosphothreonine 212-specific antibody. Results shown
in Fig. 7C, provide further evidence that PAK-Thr212 is a major
target for ERK phosphorylation.
To determine whether Thr212 is phosphorylated by ERK in
cells, we treated SMC with PDGF-BB for various times and
examined the phosphorylation of PAK1-Thr212 (pThr212) by
Western analysis. As shown in Fig. 8A, PDGF-BB stimulated a
time-dependent increase in pThr212 that lagged slightly behind
FIG. 3. ERK precipitates from SMC cell lysate with GST-PAK1
fusion protein. SMC were serum-starved for 4 h before treatment
with PDGF-BB (20 ng/ml) for the times indicated. Lysates were incu-
bated with 30 g of purified GST-PAK1 (amino acids 1–290) for 30 min,
and complexes were precipitated and analyzed by SDS-PAGE as de-
scribed under “Experimental Procedures.” A, Western blotting was
performed using an antiphospho-ERK1/2 antibody (pERK, top panel).
Middle and bottom panels represent a 10% lysate loading control for
phospho-ERK1/2 and total ERK2, respectively. B, pull-downs were per-
formed in triplicate for each time point. Western blotting was performed
with an antibody recognizing total ERK1/2. Data are representative of
three to five separate experiments.
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FIG. 6. PAK1 does not phosphorylate ERK2 in vitro. An in
vitro kinase assay was performed with purified His-PAK1 (lanes 1–4),
kinase-defective ERK2 (KD-ERK; lanes 9–12), or both (lanes 5–8) in
the presence of [-32P]ATP for 10 min at 30 °C as described under
“Experimental Procedures.” Samples were examined by SDS-PAGE,
and the gel was either dried and exposed to Kodak XAR imaging film
for 2 h (top), or rehydrated and stained with Coomassie Blue R-250 to
reveal KD-ERK loading (bottom). Data are representative of two
separate experiments.
FIG. 4. ERK2 binds directly to N terminus of PAK1. A, indicated
concentrations of immobilized GST-PAK1 (amino acids 1–290) was
electrophoresed, transferred to nitrocellulose, incubated with purified
His-ERK2 protein, then probed with anti-His antibody as described
under “Experimental Procedures” (top). Western blot was stripped and
reprobed with an anti-GST antibody to reveal the amount of GST-PAK1
loaded at the indicated concentrations (bottom). B, His-ERK2 (left),
GST, and GST-PAK1 (right) proteins were purified as described under
“Experimental Procedures.” Proteins (5 g) were analyzed on a 12%
SDS-acrylamide gel and stained with Coomassie Blue. Mass spectral
analysis revealed that the higher molecular mass band in the GST-
PAK1 lane (denoted P1) contains GST and amino acids 1–290 of PAK1
and the lower molecular mass band (denoted P2) contains GST and
amino acids 1–55 of PAK1. C, Far Western was performed as described
above using GST or GST-PAK1-(1–55) as bait and His-ERK2 as a probe.
The membrane was probed with anti-His antibody (top) and then
stripped and reprobed with an anti-GST antibody to reveal the amount
of GST and GST-PAK1 (amino acids 1–55) loaded at the indicated
concentrations (bottom). D, PAK1 SPOT peptide membrane was blocked
and incubated with purified His-ERK2 protein as described under “Ex-
perimental Procedures.” The membrane was probed with an anti-ERK
antibody and binding was detected by chemiluminescence. Three bind-
ing sites were identified by chemiluminescence and labeled site A,
amino acids 40–54, B, amino acids 86–94; and C, amino acids 124–138.
The first row of the grid contains 12-mer random control peptides and
the remaining square contains overlapping 12-mers derived from the
PAK1 sequence. Data in panels A–C are representative of at least three
separate experiments.
FIG. 5. A, equal amounts of pooled SMC lysate (500 g) were incu-
bated with either GST-PAK (25 g) or a GST-PAK variant lacking
amino acids 40–54 (GST-DA, 25 g), and complexes were precipitated
and analyzed by SDS-PAGE and Western blotting as described above
(top panel). A7R5 cells were transfected with FLAG-L61 Rac, cells were
lysed 48-h post-transfection, lysates were pooled, and 500 g of protein
were incubated with 25 g of GST-PAK or GST-DA as described above.
Western blotting was performed with an anti-FLAG antibody (bottom
panel). B, A7R5 cells were transfected with 0.75 g of SRE-luciferase
reporter plasmid along with 0.25 g of either GFP-C1, GFP-PAK, or
GFP-PAKDA. 48-h post-transfection, cells were lysed and analyzed for
luciferase activity. The inset shows equivalent expression levels of the
GFP-PAK1 and GFP-PAKDA constructs. Data were normalized to total
cellular protein. The graph represents mean  S.E. of four separate
experiments. The single asterisk indicates significant increases from
control GFP-transfected cells (p  0.05).
PAK1 Binds to and Is Phosphorylated by ERK2 2059
activation of ERK, with an observed peak in phosphorylation
around 10 min (Fig. 8A). Pretreatment of SMC with the MEK
inhibitor, UO126, almost completely blocked PDGF-BB-stimu-
lated PAK1 phosphorylation, indicating that this response is
mediated by ERK signaling. Interestingly, although adhesion
signaling can stimulate association between ERK and PAK,
plating on fibronectin alone for 30–90 min is not sufficient to
induce pThr212 (Fig. 7B). Nonetheless, adhesion is required for
PDGF-BB stimulated pThr212, since PDGF-BB treatment of
SMC held in suspension did not alter pThr212 levels (Fig. 8C).
Recent reports demonstrated that Cdc2/Cdk5 can phospho-
rylate PAK1-Thr212 in a cell cycle-dependent manner (35–38).
To rule out the possibility that these cyclin-dependent kinases
are involved in PDGF-BB-stimulated Thr212 phosphorylation,
we exposed SMC to the Cdk1 inhibitor alsterpaullone prior to
PDGF-BB stimulation and examined the level of Thr212 phos-
phorylation. As shown in Fig. 9A, the cyclin-dependent kinase
inhibitor did not diminish Thr212 phosphorylation. Interest-
ingly, PDGF-BB inhibited Cdc2/Cdk5 activity in SMC as meas-
ured by the inhibitory phosphorylation of Cdc2-Tyr15 (Fig. 9B)
further suggesting that adhesion-dependent agonist-stimu-
lated phosphorylation of PAK1-Thr212 in SMC is dependent
upon ERK and not Cdc2/Cdk5.
Irrespective of the kinases involved, phosphorylation of
PAK1-Thr212 has been implicated in the regulation of post-
mitotic cell spreading and microtubule organization (35–37). In
addition, phospho-ERK1/2 and -PAK1 co-localize in focal adhe-
sion structures in SMC, so we hypothesized that PAK-Thr212
phosphorylation might regulate focal adhesion formation. To
this end, we transfected GFP-tagged variants of PAK1 includ-
ing a non-phosphorylatable Thr212 (T212A) and one that mim-
ics phosphorylation, T212E, into A7R5 SMC that were then
plated onto fibronectin for 20–90 min. No change in the rate of
cell spreading was observed between GFP-PAK1-, GFP-
PAKT212A-, or GFP-PAKT212E-expressing cells (data not
shown). Furthermore, each of the variants localized in focal
adhesions and had no effect on the organization of nascent or
mature focal adhesions as assessed by paxillin and vinculin
staining, respectively. Organization of actin microfilaments
and acetylated tubulin were also indistinguishable between
wild-type GFP-PAK1 and the phosphorylation variants (Fig.
10).
Because PAK potentiates ERK activation, we sought to de-
termine whether PAK-Thr212 phosphorylation might regulate
ERK-PAK association and/or ERK-dependent signaling. GST-
PAK, GST-PAK pretreated with purified active ERK2, and
[-32P]ATP, and GST-PAKT212E each precipitated similar
amounts of ERK from SMC lysates, indicating that pThr212
does not attenuate ERK-PAK association (data not shown). To
determine the possible effects of Thr212 phosphorylation on
downstream signaling, we examined the effect of GFP-PAK and
GFP-PAKT212E expression on transactivation of the ERK-de-
pendent SRE-luciferase reporter gene. As shown in Fig. 10, in
contrast to GFP-PAK, which stimulated serum-induced lucif-
FIG. 7. ERK2 phosphorylates PAK1
on Thr212 in vitro. A, equal amounts of
GST and GST-PAK1 (5 g) were incu-
bated with purified active ERK2 (10 ng)
and [-32P]ATP for 10 min at 30 °C as
described under “Experimental Proce-
dures.” Samples were analyzed by SDS-
PAGE, and the gel was either stained
with Coomassie Blue R-250 (left), or dried
and exposed to Kodak XAR film for 20
min (right). B, in vitro kinase assay was
performed as described above with equal
amounts of GST, GST-PAK1 (WT), GST-
PAK1T212A (212A), GST-PAK1S223A
(223A), or GST-PAK1T212A/S223A
(212A/223A). Coomassie-stained gel
shows equal loading for each variant
(left), and the autoradiograph reveals
level of ERK2-stimulated phosphoryla-
tion (right). C, 0.3 g of GST-PAK1 was
incubated with () or without () active
ERK2 (10 ng) and cold ATP (50 M) for 10
min at 30 °C as described under “Experi-
mental Procedures.” Samples were ana-
lyzed by SDS-PAGE, the gel was trans-
ferred to nitrocellulose, and a Western
blot was performed using an anti-pThr212
PAK1 antibody (top). The membrane was
stripped and reprobed using an anti-GST
antibody (bottom) to reveal equal loading.
Data are representative of at least three
separate experiments.
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erase activity, GFP-PAKT212E expression markedly attenu-
ated this response. Based on the observations presented in this
report, we hypothesize that Rac-dependent adhesion signaling
activates PAK and induces an association between PAK and
components of the ERK signaling cascade to facilitate ERK sig-
naling, and that subsequent growth factor stimulated phospho-
rylation of PAK-Thr212 by ERK may serve to provide a negative
feedback signal to control coordinate activation of ERK by growth
factor- and matrix-induced signals (see Fig. 11).
DISCUSSION
PAK kinases regulate various cellular processes such as
proliferation, migration, contraction, and apoptosis. PAK1 is a
Rac/Cdc42 effector that coordinates actin-based cellular protru-
sions, an important step in persistent directional migration
(39, 40). Recent studies reveal that PAK1 activity is also es-
sential for maximal activation of the mitogenic Raf/MEK/ERK
cascade (40). Indeed, PAK can synergize with Ras to activate
Raf and can synergize with MEK to activate ERK (5, 14, 17, 18,
20–22). Herein we report that ERK2 associates with PAK1 in
an adhesion-dependent manner through sites mapped within
the N-terminal autoinhibitory domain of PAK. In addition, we
show that a PAK deletion variant that does not readily associ-
ate with ERK, has a reduced capacity to enhance ERK-depend-
ent transactivation of an SRE-reporter construct. These data
are consistent with previous findings that adhesion-dependent
Rac activation is required for efficient accumulation of active
ERK in the nucleus (41, 42). The ability of PAK to bind (and
phosphorylate) Raf, phosphorylate MEK and, as demonstrated
in this study, bind to ERK, indicates that PAK may serve as a
scaffold to recruit members of the RafMEKERK complex to
focal adhesions and subsequently facilitate signaling through
the ERK pathway (Fig. 12).
In yeast, Ste5, which regulates activation of the Fus3 MAP
kinase mating pathway is a classic example of a high fidelity
signaling scaffold, because it interacts with each member of the
cascade (Ste20, Ste11, Ste7, and Fus3) (43, 44). To date, a protein
that acts in an analogous fashion to Fus3 in the ERK cascade has
not been identified. However, kinase suppressor of Ras (KSR)
and MEK-binding partner 1 (MP-1) are putative ERK scaffolding
molecules, because they bind directly to both MEK and ERK
(specifically MEK1 and ERK1 in the case of MP-1) (45, 46).
Herein, we have shown that PAK (the Ste 20 homologue or
MAP4K of the ERK pathway) interacts with ERK2 through a
region within the N-terminal autoinhibitory domain. Because
PAK has also been shown to interact with Raf within sequences
in the C terminus, it may serve as an additional potential scaffold
for the ERK cascade. Even though there is no evidence of a direct
PAK-MEK interaction, it has been shown that upon Raf binding
to the C terminus of PAK, MEK becomes phosphorylated at
Ser298, a site required for maximal MEK activation (14, 18).
Furthermore, Slack-Davis et al. (21) showed that adhesion in-
duces PAK-dependent phosphorylation of MEK-Ser298, and El-
ben et al. (22) have shown that PAK activation was required for
adhesion-dependent association of MEK1 with ERK. Based on
these reports, it is possible that PAK1 could function to target
Raf, MEK, and ERK to nascent focal adhesions to impart re-
stricted activation of the ERK cascade at the leading edge of the
cell during migration.
We identified three distinct ERK2 binding sites that mapped
within the N-terminal autoinhibitory domain of PAK1: amino
acids 40–54, 86–94, and 124–138 (denoted A, B, and C respec-
tively). Although the reported crystal structure of the complex
between the N-terminal autoregulatory fragment (amino acids
70–149) and the C-terminal kinase domain (amino acids 249–
545) of PAK1 does not contain the most proximal A binding
site, the structure reveals that the -sheet comprising the “B”
binding site packs tightly against the -helix comprising the
“C” binding site, indicating that the binding sites for ERK2 that
we defined may indeed constitute a single binding pocket
within PAK1. Interestingly, the “A” binding site in PAK1,
which we have shown is sufficient for ERK binding does con-
tain a cluster of basic residues similar to the “D-domain” found
in other ERK binding partners including MEK, MAPK phos-
phatase, and ribosomal S6 kinase (47, 48). This motif has been
shown to function independently (47, 48), corroborating our Far
Western data revealing that PAK amino acids 1–55 were suf-
ficient for directing the ERK2-PAK1 interaction, and our find-
ings that a GST-PAK fusion protein with a deletion of amino
acids 40–54 had a markedly reduced capacity to precipitate
ERK from SMC lysates compared with the full N-terminal
construct. Future mutagenesis experiments will aid in deter-
mining the relative contribution of the defined sites to direct
high affinity binding to ERK. Notably, the 12-amino acid core of
each of the defined binding sites in PAK1 are highly conserved
across the Group I PAK family members (100, 100, and 75%
identical for A, B, and C, respectively); thus, it is likely that
ERK may interact with PAK2 and PAK3 as well as PAK1. In
fact, a recent report by Shin et al. (49) highlights the possibility
that ERK1 and PAK2 may indeed associate in cells in a fibro-
FIG. 8. PDGF-mediated Thr212 PAK1 phosphorylation in SMC
is dependent on both ERK and adhesion signaling. A, SMC were
serum-starved and treated with PDGF-BB (20 ng/ml) for times indi-
cated with or without a prior 30-min pretreatment with U0126 (10 M).
Cell extracts were prepared, and samples were examined by Western
blotting using anti-pThr212 PAK1, anti-PAK1, anti-pERK1/2, and anti-
ERK2 antibodies. B, SMC were either held in suspension (S) or plated
on fibronectin for the indicated times or treated with 20 ng of PDGF-BB
for 10 min after plating (). Western blotting was performed using
anti-pT212 PAK1 and anti-PAK1 antibodies. C, SMC were either held
in suspension or plated on fibronectin for 90 min. Cells were treated
with PDGF-BB (20 ng/ml) for the times indicated. Western blotting was
performed using anti-pThr212 PAK1 and anti-PAK1 antibodies.
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blast growth factor-dependent fashion as determined by co-
immunoprecipitation. In addition, the authors reported that a
GST-ERK1 fusion protein could precipitate exogenously ex-
pressed PAK2 from cell lysates, although a direct association
between the two proteins has yet to be demonstrated (49).
The location of the ERK2 binding site indicates the likelihood
that ERK association with full-length PAK in vivo may require
preactivation of PAK by Rac and/or Cdc42. Recent structural
studies have indicated that the inactive autoinhibited confor-
mation of PAK1 is an asymmetric dimer, whereby the autoin-
hibitory domain of one molecule associates tightly with the
kinase domain of another (34). Binding of GTP-loaded Cdc42 or
Rac with the CRIB domain disrupts the dimer, unfolds the
protein, and exposes the autoinhibitory domain allowing for
subsequent protein-protein interactions (34). Indeed, the asso-
ciation of PAK1 and ERK following cell adhesion mimicked the
time course we observed for Rac activation following plating
cells on fibronectin (23). Thus, it is possible that recruitment of
ERK to PAK may be dependent on integrin-dependent Rac
activation.
We also show that adhesion-dependent association of PAK
and ERK can provide an additional means of regulation by
driving phosphorylation of PAK by ERK. The time course of
PAK1 phosphorylation, inhibition of phosphorylation by
UO126, and the fact that ERK2 directly phosphorylated PAK1
in vitro on the same site that is also phosphorylated after
PDGF-BB treatment of SMC all support the possibility that
PAK1 is an in vivo substrate for ERK. Interestingly, although
the data presented in this report are consistent with PAK-
Thr212 being an in vivo target for ERK in SMC, other reports
have clearly shown that Thr212 is also a target for Cdc2/Cdk5 in
cells undergoing mitosis (35–38). Two lines of evidence rule out
the possibility that PAK1 is a target for Cdc2/Cdk5 following
FIG. 9. PDGF-BB-stimulated Thr212 PAK1 phosphorylation in SMC is not dependent on Cdc2/Cdk5 activity. A, serum-starved SMC
were pretreated for 3 h with alsterpaullone (10M) prior to PDGF-BB (20 ng/ml) treatment for the indicated times. Samples were electrophoresed,
and Western blotting was performed with anti-pThr212 PAK1 (top panel) or anti-PAK1 antibodies (bottom panel). B, serum-starved SMC were
treated with PDGF-BB (20 ng/ml) for times indicated. Cell extracts were prepared, and samples were examined by Western blotting using an
anti-pTyrCdc2 antibody. Data are representative of at least three separate experiments.
FIG. 10. PAK1 Thr212 phosphorylation does not alter focal ad-
hesion localization, formation, or cell spreading. A7R5 cells
transfected with GFP-PAK, GFP-PAKT212A, or GFP-PAKT212E were
trypsinized and plated on fibronectin-coated chamber slides (10 g/ml)
for 1 h as described under “Experimental Procedures.” Cells were fixed,
permeabilized, and either observed by direct fluorescence (GFP, top
panel) or stained with anti-vinculin or anti-paxillin antibodies to exam-
ine mature and nascent focal adhesions respectively, or phalloidin or
anti-acetylated tubulin antibody to examine actin or tubulin polymeri-
zation. Arrows indicate GFP-PAK1-, GFP-PAK1 T212A-, or GFP-PAK1
T212E-expressing cells identified by direct fluorescence. Data are rep-
resentative of at least three separate experiments scoring 100–150
transfected cells for each treatment.
FIG. 11. Thr212 phosphorylation suppresses SRE activation.
A7R5 cells were transfected with an SRE-luciferase reporter plasmid
along with either GFP-C1 vector control, GFP-PAK1, or GFP-PAKT212E.
48 h following transfection, cells were lysed and analyzed for luciferase
activity as described under “Experimental Procedures.” The inset shows
equivalent expression levels of the GFP-PAK1 and GFP-PAKT212E con-
structs. Data were normalized to total cellular protein. The graph
represents mean  S.E. of four separate experiments. The single and
double asterisks indicate significant increases or decreases from control
GFP-transfected cells, respectively (p  0.05).
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PDGF-BB-treatment of SMC. First, pretreatment of SMC with
alsterpaullone (a potent pharmacological inhibitor of Cdc2/
Cdk5) had no effect on PDGF-BB-stimulated Thr212 phospho-
rylation, whereas treatment with the MEK inhibitor U0126
almost completely inhibited the response. Second, PDGF-BB-
treatment of SMC caused a phosphorylation-dependent inacti-
vation of Cdc2, similar to what has been reported following
ERK activation in Xenopus extracts (50). Thus, at least in the
context of adhesion-dependent growth factor signaling, phos-
phorylation of PAK1 in SMC appears to be directed by ERK
and not Cdc2/Cdk5.
Unlike the ERK2 binding sites that are conserved in PAK1–3,
Thr212 is unique to PAK1. This consensus site is however con-
served in all mammalian forms of PAK1, indicating that phos-
phorylation of the site may regulate an important function. No-
tably, a previous detailed temporal analysis of pThr212 in vivo
revealed that high levels were observed in the embryonic fore-
brain, lung, kidney, intestine, and skin, but that pThr212 was
virtually undetectable in adult tissues (51). In terms of function,
previous studies indicate that the kinase activity of the PAK1
variants T212A and T212E were indistinguishable from wild-
type PAK1 (36). Previous reports also indicate that Cdc2-medi-
ated pThr212 altered the rate and extent of postmitotic spreading
of murine fibroblasts (37) and regulated microtubule dynamics
and overall morphology in neurons (35, 36). We show herein that
ectopic expression of PAK-T212A or PAK-T212E in SMC did not
alter focal adhesion formation, microtubule formation, or the rate
of cell spreading, although the consequence of PAK1 phosphoryl-
ation on focal adhesion turnover or directed cell migration has yet
to be determined. PAK-T212E did, however, attenuate serum-
stimulated ERK-dependent transcription, indicating that phos-
phorylation of this site might provide a negative feedback inhi-
bition to limit adhesion and growth factor-stimulated ERK
signaling. The precise mechanism of this inhibitory response is
not yet clear. We have determined that pThr212 within the con-
text of GST-PAK1-(1–290) does not alter the association of ERK
and PAK in vitro, indicating that ERK can still bind PAK-
pThr212. However, Thr212 is located within the core of a canonical
SH3-binding motif, thus it is feasible that phosphorylation of this
site could modulate association with a binding partner that could
in turn regulate ERK phosphorylation or nuclear translocation.
Experiments to address this question are presently underway.
In summary, we have shown that ERK2 binds within the N
terminus of PAK1 and when activated by adhesion-dependent
growth factor signaling, phosphorylates PAK1 on Thr212. Our
present data, together with previous reports that illustrate a
role for PAK in the regulation of the ERK cascade, indicate that
PAK1 may function as a scaffold for this canonical pathway.
Why would the ERK pathway require so many scaffolds? One
possible explanation may be that scaffolding controls local ac-
tivation of this seemingly promiscuous pathway. For example,
KSR has been shown to shuttle from the cytoplasmic mem-
brane to the plasma membrane following growth factor treat-
ment, and p14, a partner of the putative scaffold, MP1, targets
MP1-MEK1 and ERK1 to late endosomes/lysosomes (52–54). In
the case of PAK, association of the complex could lead to the
targeting of active ERK to focal adhesions. Since association of
ERK with PAK may be dependent on adhesion-induced activa-
tion of Rac, one might speculate that adhesion-stimulated PAK-
dependent targeting of ERK to these dynamic sites might reg-
ulate directional lamellipodial extension during cell migration.
Notably, studies have shown that ERK activation enhances
focal adhesion turnover by enhancing the rate of focal adhesion
disassembly (55). This effect could be caused by the ability of
ERK to phosphorylate and regulate several focal adhesion pro-
teins such as paxillin, MLCK, and calpain II (56–58). We have
also shown that coordinate signaling through adhesion and
growth factors regulates phosphorylation of PAK on Thr212,
and provide evidence that this event may decrease subsequent
ERK-dependent signaling. It is likely that ERK signaling
would have to be tightly regulated in a temporal fashion in
order for directed cell migration to occur, thus negative feed-
back phosphorylations such as Thr212 may prove important in
controlling this dynamic cellular process.
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